학술논문
Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021.
Document Type
Academic Journal
Author
Marra AR; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.; Miraglia JL; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Malheiros DT; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Guozhang Y; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Teich VD; Hospital Israelita Albert Einstein, São Paulo, Brazil.; da Silva Victor E; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Rebello Pinho JR; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Cypriano A; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Vieira LW; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Polonio M; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Ornelas RH; Hospital Israelita Albert Einstein, São Paulo, Brazil.; de Oliveira SM; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Borges Junior FA; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Oler SCC; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Schettino GPP; Hospital Israelita Albert Einstein, São Paulo, Brazil.; de Oliveira KG; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Ferraz Santana RA; Hospital Israelita Albert Einstein, São Paulo, Brazil.; de Mello Malta F; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Amgarten D; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Boechat AL; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Trecenti NMZ; Hospital Israelita Albert Einstein, São Paulo, Brazil.; Kobayashi T; Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.; Salinas JL; Stanford University, Stanford, California, USA.; Edmond MB; West Virginia University School of Medicine, Morgantown, West Virginia, USA.; Rizzo LV; Hospital Israelita Albert Einstein, São Paulo, Brazil.
Source
Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Little is currently known about vaccine effectiveness (VE) for either 2 doses of Oxford-AstraZeneca (ChAdOx1) viral vector vaccine or CoronaVac (Instituto Butantan) inactivated viral vaccine followed by a third dose of mRNA vaccine (Pfizer/BioNTech) among healthcare workers (HCWs).
Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) working in a private healthcare system in Brazil from January to December 2021. VE was defined as 1 - incidence rate ratio (IRR), with IRR determined using Poisson models with the occurrence of laboratory-confirmed coronavirus disease 2019 (COVID-19) infection as the outcome, adjusting for age, sex, and job type. We compared those receiving viral vector or inactivated viral primary series (2 doses) with those who received an mRNA booster.
Results: A total of 11 427 HCWs met the inclusion criteria. COVID-19 was confirmed in 31.5% of HCWs receiving 2 doses of CoronaVac vaccine versus 0.9% of HCWs receiving 2 doses of CoronaVac vaccine with mRNA booster (P < .001) and 9.8% of HCWs receiving 2 doses of ChAdOx1 vaccine versus 1% among HCWs receiving 2 doses of ChAdOx1 vaccine with mRNA booster (P < .001). In the adjusted analyses, the estimated VE was 92.0% for 2 CoronaVac vaccines plus mRNA booster and 60.2% for 2 ChAdOx1 vaccines plus mRNA booster, when compared with those with no mRNA booster. Of 246 samples screened for mutations, 191 (77.6%) were Delta variants.
Conclusions: While 2 doses of ChAdOx1 or CoronaVac vaccines prevent COVID-19, the addition of a Pfizer/BioNTech booster provided significantly more protection.
Competing Interests: Potential conflicts of interest. A. L. B. reports the following contracts or grants unrelated to this work: MCTIC/CNPq/FNDCT/MS/SCTIE/Decit 07/2020, Brazil. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
(© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) working in a private healthcare system in Brazil from January to December 2021. VE was defined as 1 - incidence rate ratio (IRR), with IRR determined using Poisson models with the occurrence of laboratory-confirmed coronavirus disease 2019 (COVID-19) infection as the outcome, adjusting for age, sex, and job type. We compared those receiving viral vector or inactivated viral primary series (2 doses) with those who received an mRNA booster.
Results: A total of 11 427 HCWs met the inclusion criteria. COVID-19 was confirmed in 31.5% of HCWs receiving 2 doses of CoronaVac vaccine versus 0.9% of HCWs receiving 2 doses of CoronaVac vaccine with mRNA booster (P < .001) and 9.8% of HCWs receiving 2 doses of ChAdOx1 vaccine versus 1% among HCWs receiving 2 doses of ChAdOx1 vaccine with mRNA booster (P < .001). In the adjusted analyses, the estimated VE was 92.0% for 2 CoronaVac vaccines plus mRNA booster and 60.2% for 2 ChAdOx1 vaccines plus mRNA booster, when compared with those with no mRNA booster. Of 246 samples screened for mutations, 191 (77.6%) were Delta variants.
Conclusions: While 2 doses of ChAdOx1 or CoronaVac vaccines prevent COVID-19, the addition of a Pfizer/BioNTech booster provided significantly more protection.
Competing Interests: Potential conflicts of interest. A. L. B. reports the following contracts or grants unrelated to this work: MCTIC/CNPq/FNDCT/MS/SCTIE/Decit 07/2020, Brazil. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
(© The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)